The effects of Alendronate on bone mineral density in RA patients with osteoporosis or osteopenia

许蓓,林进,徐立勤,徐丹怡,曹恒,陈伟钱

DOI: https://doi.org/10.3969/j.issn.1673-7555.2011.14.004

2011-01-01

Abstract:Objective To investigate the effects of alendronate on BMD in RA patients with osteoporosis or osteopenia Methods Forty two RA patients with standard treatment of Methotrexate 10 mg/w,Folic acid 5 mg/d,and vitamin D_3 600 mg/d,were randomly divided into two grous Compare to the control arm,the experimental arm added alendronate to standard treatment for 6 months BMD of the spine(L_1~4),femoral neck,trochanter,and Ward's triangle region,as well as RA disease activity index,were evaluated and analyzed for correlation in both groups prior to the randomization and after completion of six month treatment Results Spine BMD in the experimental group after six month treatment was significantly improved compared with the baseline measurement(P<0.05),which was also superior to the control group(P<0.05) BMD of the femoral neck,trochanter,and Ward's triangle region were elevated without statistical significance compared to the baseline and control group However,the improvement of BMD after six month alendronate treatment in the experimental group had no correlation with RA disease activity index including ESR,CRP,RF,HAQ scale,number of swollen joints,number of painful/tender joints,and DAS28 score Conclusion Adding alendronate to conventional anti rheumatic drugs can improve the spine BMD in RA patients with osteoporosis or osteopenia,and may have critical clinical implications in the treatment strategy of RA.